Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAcurx Pharmaceuticals LLC

Acurx Pharmaceuticals LLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.075 USD 0.01 ( 1.42%)
Last update at 2026-11-09T20:48:00Z
VOLUME
104681
Market Cap
6.74M

Momentum Score

…

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.06
Low
1.12
High
52 Week Price Range
1.33
Low
21.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Acurx Pharmaceuticals LLC (NASDAQ: ACXP) is a publicly listed biopharmaceutical company; available public information is limited. It appears positioned in infectious-disease drug development, where long-term growth may be driven by clinical progress, regulatory approvals and potential licensing or partnership deals. Investors may find the company attractive for upside linked to pipeline milestones and future commercialization opportunities.
Primary risks include early-stage clinical and regulatory uncertainty, a likely need for additional financing, limited operating history and low liquidity that could increase share price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.06
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-270.80%
Net Debt
-7556.10M
ROCE
-153.59%
Diluted EPS TTM
-5.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.97M -14.10M -14.58M -12.09M -12.75M
Net income -7.97M -14.10M -14.58M -12.09M -12.68M
Selling general administrative 6257.48M 8.70M 8.53M 7.34M 10.78M
Selling and marketing expenses - 8690.57M 8525.64M - -
Ebit - -14.10M -29.16M -12.09M -12.95M
Ebitda -8.09M -14.10M -14.58M -12.09M -12.88M
Depreciation and amortization - 14.10M 14.58M 0.00M 0.07M
Operating income -8.09M -14.10M -14.58M -12.09M -12.88M
Other operating expenses 8.09M 14.10M 14.58M 12.09M 12.81M
Interest expense - - - 0.00M 0.07M
Interest income 0.13M 0.02M - - -
Net interest income 0.13M 0.02M - - -
Income tax expense - -14089.00M -0.01M -0.00M -0.07M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 8.09M 14.10M 14.58M 12.09M 12.81M
Total other income expense net 0.13M 0.00M 0.00M 0.00M 0.13M
Net income from continuing ops -7.97M -14.10M -12.72M -12.09M -12.75M
Net income applicable to common shares - - - -12.09M -12.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.69M 3.86M 7.71M 9.38M 13.25M
Other current assets -7548.46M 0.10M 0.11M - 0.30M
Total liab 2.42M 3.24M 3.04M 2.06M 0.84M
Total stockholder equity 5.27M 0.62M 4.67M 7.32M 12.41M
Other current liab 2.42M 3.24M 3.04M - 0.84M
Common stock 0.00M 0.02M 0.01M 0.01M 0.01M
Capital stock 0.00M 0.02M 0.01M 0.01M 0.01M
Retained earnings -75.29M -67.32M -53.22M -38.64M -26.55M
Other assets 133.44M 151.25M 234.94M 0.26M 295.30M
Cash 7556.10M 3.71M 7.47M 9.11M 12.96M
Total current liabilities 2.42M 3.24M 3.04M 2.06M 0.84M
Net debt -7556.10M -3.71M -7.47M -9.11M -12.96M
Other stockholder equity 80.55M 67.92M 57.87M 84.59M 65.50M
Total current assets 7.69M 3.86M 7.71M 9.38M 13.25M
Net tangible assets - - - 7.32M 12.41M
Net receivables 0.05M 0.05M 0.13M - -
Accounts payable - - 0.00M 2.06M 0.84M
Accumulated other comprehensive income - - - -38.64M -26.55M
Non currrent assets other 133.44M - - - -
Non current assets total 133.44M 3854.11M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - 1.22M 0.39M
Total cash from financing activities 10637.17M 6.62M 8.16M 3.70M 14.80M
Change to operating activities - - - 0.03M -0.25M
Net income -7966.54M -14.10M -14.58M -12.09M -12.75M
Change in cash 3849.39M -3.77M -1.64M -3.85M 9.78M
Begin period cash flow 3706.71M 7.47M 9.11M 12.96M 3.18M
End period cash flow 7556.10M 3.71M 7.47M 9.11M 12.96M
Total cash from operating activities -6787.78M -10.38M -9.80M -7.54M -5.01M
Issuance of capital stock 6.80M 6.41M 3.54M 3.70M 14.80M
Other cashflows from investing activities - - -0.00M - -
Change to inventory - - -980.75M - -
Change to account receivables 0.00M 0.08M -0.13M - -
Sale purchase of stock 3808.44M 0.00M - - -
Other cashflows from financing activities 10626.53M 0.21M 2.22M 0.00M 14.80M
Change to netincome - - - 3.30M 7.59M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.39M 0.28M 1.01M 1.25M 0.14M
Stock based compensation 1247.40M 3.44M 3.77M 3.30M 6.74M
Other non cash items -68.25M -0.00M 0.00M - 0.85M
Free cash flow -6787.78M -10.38M -9.80M -7.54M -5.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ACXP
Acurx Pharmaceuticals LLC		 0.01
1.42%		 1.07 - - - 1.28 -3.54
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

259 Liberty Avenue, Staten Island, NY, United States, 10305

917 533 1469

https://www.acurxpharma.com

4

Name Title Year Born
Mr. Robert J. DeLuccia Co-Founder & Exec. Chairman 1946
Mr. David P. Luci CPA, CPA, Esq., J.D. Corp. Sec., Co-Founder, Pres, CEO & Director 1967
Mr. Robert G. Shawah CPA, CPA Co-Founder & CFO 1967
Mr. Robert J. DeLuccia Co-Founder & Executive Chairman 1946
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO & Director 1967
Mr. David P. Luci CPA, Esq., J.D. Co-Founder, President, CEO, Corporate Secretary & Director 1967
Mr. Robert G. Shawah CPA Co-Founder & CFO 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…